Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

nintedanib

- PMLiVE

ABPI names first project director for manufacturing

James Christie joins from Oxford BioMedica

UK flag

UK lags behind other countries in use of branded drugs

ABPI claims use of innovative new treatments is lower than international average in seven out of 11 classes

EU flag

Boehringer’s Vargatef approved in the EU for lung cancer

Marks company’s second oncology drug to hit market

- PMLiVE

Stratified medicines face uptake challenges in the NHS

But 90% of HCPs believe the area will have a positive impact on the health system

- PMLiVE

Integrating digital: developing a social conference

Boehringer Ingelheim’s director of oncology Albert van Eijk on the digital elements of its multichannel efforts

- PMLiVE

Former Vodafone UK comms head joins ABPI

Aileen Thompson appointed director of communications at UK pharma trade body

- PMLiVE

NICE backs Boehringer’s blood clot treatment Pradaxa

Draft DVT and PE guidance puts it on course to catch up with Bayer's Xarelto

- PMLiVE

Boehringer’s Ofev approved by FDA for rare lung disease

US regulator also gives the green light to Intermune's Esbriet

ABPI London offices

Half of England’s adults say NHS spends too little on drugs

Medicines account for 10p of every £1 spent by NHS, says ABPI

- PMLiVE

Boehringer Ingelheim launches Sound Challenge app

Looks to raise awareness of rare lung disease IPF

- PMLiVE

NHS ‘not driving’ health innovation

Minister for Life Sciences acknowledges UK has more to do

- PMLiVE

ABPI-backed study causes Servier Code of Practice breach

Company failed to disclose study results in suitable time

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links